Silence-Logo-FINAL-rgb.png
Silence Therapeutics Welcomes Deep Track Capital as New Shareholder
December 01, 2021 07:00 ET | Silence Therapeutics plc
1 December 2021 LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA)...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics Begins Exclusive Nasdaq Trading
November 30, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics Begins Exclusive Nasdaq Trading 30 November 2021 LONDON, Silence Therapeutics plc, Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics to Present at Jefferies London Healthcare Conference
November 11, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics to Present at Jefferies London Healthcare Conference 11 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder
November 05, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder 5 November 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day
October 21, 2021 08:30 ET | Silence Therapeutics plc
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication...
Silence-Logo-FINAL-rgb.png
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market
October 15, 2021 07:05 ET | Silence Therapeutics plc
Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market Notice of General Meeting to be...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform
October 15, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform Hansoh will make a $16 million upfront cash payment and Silence has the...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics to Host R&D Day on October 21, 2021
October 07, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics to Host R&D Day on October 21, 2021 7 October 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference
September 28, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics to Participate in Fireside Chat at the Chardan Virtual Genetic Medicines Conference 28 September 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or...
Silence-Logo-FINAL-rgb.png
Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development
September 01, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics Appoints Dr. John Strafford as Senior Vice President, Business Development, Alliance Management and New Product Development 1 September 2021 LONDON, Silence Therapeutics plc,...